Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

CFO

Kurt.leutzinger@pharmasset.com

Office: 609-613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that the final results of the third and fourth cohorts of the 4-week Phase I clinical trial evaluating R7128 will be materially different from the preliminary results, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , ... /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the ... of cancer, today announced the dosing of the first patient under ... Therapy in prostate cancer patients. The study will evaluate the localization, ...
... 11 Allscripts (Nasdaq: MDRX ) announced today ... centers of the mid-South and the flagship of Vanderbilt University Medical ... ensure continuity of care and improve the efficiency of the hospital patient ... , (Logo: ...
... --, -- Revenue increased 26.4% to $26.1 million, ... than 200 basis points to 10.3%; Adjusted diluted EPS increased ... -- Sales of PurCotton(R) products increased 71.1% to $1.9 Million, ... the first six months in fiscal year 2009, ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3Vanderbilt University Hospital Selects Allscripts Care Management 2Vanderbilt University Hospital Selects Allscripts Care Management 3Vanderbilt University Hospital Selects Allscripts Care Management 4Vanderbilt University Hospital Selects Allscripts Care Management 5Vanderbilt University Hospital Selects Allscripts Care Management 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 2Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 3Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 4Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 5Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 7Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 8Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 9Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 10Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 11Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 12Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 13Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 14Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 15Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 16Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 17Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 18Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 19
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/18/2014)... A team of researchers led by a ... selected to receive a $7.5 million Department of Defense ... and basic scientific foundations for the predictable design of ... wide diversity of structures from plants and animals, including ... taking what biological systems have constructed over millions of ...
(Date:4/17/2014)... CHAMPAIGN, Ill. A drug under clinical trials to ... of broad-spectrum drugs that act against various bacteria, fungal ... study by University of Illinois chemists and collaborators. , ... the team determined the different ways the drug SQ109 ... tweaked to target other pathogens from yeast to malaria ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... celebrates distinguished government scientist Professor Robert (Bob) Watson who ... Chief Scientific Advisor to the Department of Environment, ... alumnus, Professor Watson is recognised for his contributions to ... and global warming. Professor Peter Heathcote, Head of ...
... A Cardiff University researcher has secured a highly sought-after ... stage. Dr Paola Borri, Cardiff School of Biosciences, is ... interface between life and physical sciences Now, she has ... Leadership Award for the next five years. This will support ...
... at Virginia Tech have constructed a mathematical and computational ... simulate the cellular and molecular changes underlying chronic inflammation ... explore different interactions of cells in the immune system, ... the colon, and identify intervention points to perhaps stop ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2Boost for world-leading microscopy project 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3
... SBED Protein:Protein Interaction Reagent A powerful ... rapidly gained traction as an in vitro ... number of publications feature the exclusive Pierce ... study a variety of issues relating to ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
Biology Products: